Bionomics (ASX: BNO) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Bionomics Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Bionomics (ASX: BNO)
    Latest News

    a woman
    52-Week Lows

    Why the Bionomics Ltd (ASX:BNO) share price crashed 69% lower today

    The Bionomics Ltd (ASX:BNO) share price has crashed 69% lower today after it released the results from its BNC210 PTSD…

    Read more »

    a woman
    Share Market News

    Why these ASX shares are in trading halts

    Blue Sky Alternative Investments Ltd (ASX:BLA) shares are one of three in trading halts today. Here's why...

    Read more »

    a woman
    Share Gainers

    Why these 4 ASX shares have climbed higher today

    The Investa Office Fund (ASX:IOF) share price is one of four climbing higher on Wednesday. Here's why...

    Read more »

    a woman
    Share Market News

    Top broker makes FY19 picks

    These shares are top picks for FY19 by Bell Potter.

    Read more »

    a woman
    Share Fallers

    Why these 4 ASX shares have started the week in the red

    The Domino's Pizza Enterprises Ltd (ASX:DMP) share price is one of four starting the week in the red. Here's what…

    Read more »

    a woman
    Healthcare Shares

    3 small cap healthcare shares to watch

    Volpara Health Technologies Ltd (ASX:VHT) shares are one of three in the healthcare sector worth watching in my opinion…

    Read more »

    a woman
    ⏸️ Investing

    2 biotech picks that could provide big returns for growth investors

    Nasdaq CEO says we are entering "the golden age" of biotechnology and these ASX shares could be part of that…

    Read more »

    a woman
    ⏸️ Investing

    2 ASX listed biotech companies to get excited about

    Are these smaller players the next CSL Limited (ASX: CSL)?

    Read more »

    a woman
    ⏸️ Investing

    2 exciting biotech shares to watch in 2018

    The CSL Limited (ASX:CSL) share price has climbed 1,100% in 14 years. Could these fledgling biotechs follow in its footsteps?

    Read more »

    a woman
    ⏸️ Investing

    3 biotech shares to watch in FY 2018

    Could one of these three biotech shares be the next CSL Limited (ASX: CSL)?

    Read more »

    a woman
    ⏸️ Investing

    3 explosive biotech shares to watch

    Spotting the next CSL Limited (ASX:CSL) could make you rich. Could one of these 3 ASX shares be the one?

    Read more »

    a woman
    ⏸️ Investing

    3 small-cap healthcare shares to watch

    The Medical Developments International Ltd (ASX:MVP) share price is one of three in the healthcare sector which I believe could…

    Read more »

    BNO ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Bionomics

    Bionomics Ltd. is a clinical stage biopharmaceutical company. It engages in the development of novel drug candidates focused on the treatment of serious central nervous system disorders. The company was founded in 1996 and is headquartered in Eastwood, Australia.

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    23 Feb 2023 Errol De Souza Issued 10,000,000 $290,000
    Director remuneration.
    23 Feb 2023 Errol De Souza Expiry 1,666,667 $48,333
    Options expired.
    23 Feb 2023 Spyridon Papapetropoulos Issued 27,067,015 $784,943
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Alan David Fisher Non-Executive Director Sep 2016
    Mr Fisher is an experienced corporate advisor and public company director. He has a track record for implementing strategies that enhance shareholder value. His main areas of expertise include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice. He is Chair of the Risk Management Committee.

    Mr Aaron Weaver Non-Executive Director Jul 2020
    Mr Weaver is a Principal at Apeiron Investments Group Ltd (Apeiron), focused on the life sciences and technology sector. From 2013 - 2017, he was an investment banker at Credit Suisse Group AG in London within the Capital Markets Solutions team, advising on capital structuring and issuances for a full spectrum of corporate issuers from pre-revenue companies to public listed companies. He was a capital markets solicitor at Allen & Overy LLP, London from 2007 - 2013. Mr Weaver currently serves on the board of Bionomics as Apeiron's nominee. He is a director of MagForce AG, LEAF4Life LLC, Alto Neuroscience, Endogena Therapeutics, Inc, Rejuveron Life Sciences AG.
    Dr Errol B De Souza Executive ChairmanExecutive Director Aug 2016
    Dr De Souza is a leader in the development of therapeutics for treatment of central nervous system (CNS) disorders. He has experience as an executive in the biopharmaceutical industry, having founded companies (Neurocrine Biosciences Inc.) and served as President and CEO of several public (Biodel Inc.; Synaptic Pharmaceutical Corp.) and private (Archemix Corp. and Neuropore Therapies Inc.) biotech companies. Dr De Souza has raised several hundred million dollars in capital in private and public sectors and has taken companies public (Neurocrine Biosciences IPO) and sold companies (Synaptic sale to Lundbeck) to provide liquidity and build shareholder value. Over Dr De Souza's career, he has served in a number of high-ranking R&D roles, including SVP and US head of R&D for Aventis (1998-2002), co-founder and EVP of R&D at Neurocrine (1992-1998) and Head of CNS at DuPont Merck (1990-1992). Dr De Souza has served on multiple editorial boards, National Institutes of Health (NIH) Committees and is currently a Director of several public and private companies and currently serves as a member of the board of directors of Catalyst Biosciences, Inc. (CBIO), Cyclerion Therapeutics (CYCN) and Royalty Pharma plc (RPRX). He has previously served on the board of directors of several public companies including IDEXX Laboratories (IDXX), Neurocrine Biosciences (NBIX), Palatin Technologies (PTN) and Synaptic Pharmaceuticals (SNAP).
    Mr David Ian Wilson Non-Executive Director Jun 2016
    Mr Wilson is Chairman and founding partner of WG Partners LLP and has over 35 years' experience in investment banking in the City of London. Previously Mr Wilson was CEO of Piper Jaffray Ltd, where he also served as Global Chairman of Healthcare and on the Group Leadership Team. Mr Wilson has held senior positions at ING Barings as Joint Head of UK Investment Banking Group, Deutsche Bank as Head of Small Companies Corporate Finance and UBS as Head of Small Companies Corporate Broking. Mr Wilson was previously Senior Independent Director of Optos plc, a Non-Executive Director of BerGenBio AS. He is member of the Risk Management Committee.
    Dr Jane Ryan Non-Executive Director Sep 2020
    Dr Ryan has over 30 years of international experience in the pharmaceutical and biotechnology industries having worked in Australia, US and UK. She has held senior executive roles in management of research and development programs as well as business development and alliance management. Throughout her career, she has led many fundraising campaigns and licensing initiatives. She is member of the Risk Management Committee.
    Mr Peter Miles Winston Davies Non-Executive Director Jul 2021
    Mr Davies is a 15-year veteran of the financial services industry with multi-sector and multi-function experience. He has a track record in advising private and public company Board of Directors and shareholders of businesses. He has completed numerous M&A transactions across a variety of sectors including healthcare, along with experience in capital raising and restructuring opportunities during his time at Rothschild & Co. Mr Davies is currently an Investment Professional at Apeiron Investments Group Ltd and is Chief Business Officer for Leaf4Life Inc
    Dr Spyridon Papapetropoulos Non-Executive Director Jan 2023
    --
    Ms Suzanne Grace Irwin Company Secretary Apr 2021
    -
    Adrian Hinton Acting Chief Financial Officer
    -
    Suzanne Grace Irwin Company Secretary
    -
    Liz Doolin Vice President Clinical Development
    -
    Connor Bernstein Vice President Strategy and Corporate Development
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited <Citibank Ny Adr Dep A/C> 339,875,460 25.11%
    HSBC Custody Nominees (Australia) Limited 318,042,650 23.50%
    BNP Paribas Nominees Pty Ltd Acf Clearstream 73,460,960 5.43%
    BNP Paribas Noms Pty Ltd <DRP> 43,985,676 3.25%
    HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> 34,633,340 2.56%
    US Register Control A/C\C 32,409,786 2.39%
    Bell Potter Nominees Ltd <Bb Nominees A/C> 28,472,814 2.10%
    Citicorp Nominees Pty Limited 20,002,049 1.48%
    BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 17,995,687 1.33%
    Merrill Lynch (Australia) Nominees Pty Limited 17,901,124 1.32%
    Mr Jason Howard David Camm 9,102,132 0.67%
    L&M Group Limited 8,884,085 0.66%
    BNP Paribas Noms Pty Ltd <Global Markets Drp> 8,527,043 0.63%
    Forward Vision Vii Lp Series 2 6,830,075 0.50%
    Mr Mark Richard Potter + Mrs Rebecca Amy Potter <Mark & Rebecca Potter A/C> 5,500,000 0.41%
    Qualvest Pty Ltd <Lin Super Fund A/C> 5,000,000 0.37%
    Charmed5 Pty Ltd 5,000,000 0.37%
    Ambria Investors Lp 4,845,050 0.36%
    Provendore Pty Ltd <The Wilks Super Fund A/C> 4,418,550 0.33%
    Welas Pty Ltd <The Wales Family Super A/C> 4,403,719 0.33%

    Profile

    since

    Note